Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die
Datenschutzhinweise)
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Leider können wir deine Anfrage auf diesem Weg nicht entgegennehmen. Bitte schreibe uns an: portal.support@ariva.de
Termine
Keine Termine bekannt.
Prognose & Kursziel
Keine aktuellen Prognosen oder Kursziele bekannt.
Stammdaten
Aktienanzahl
90,39 Mio.
Aktientyp
Stammaktie
Community-Beiträge zu Medreleaf
Community-Beiträge
Aktuellste Threads
bradetti
Na guck mal an: NEWS
MedReleaf receives license amendment from Health Canada to commence sales at its Bradford Facility
https://www.tmxmoney.com/en/news/company_releases/index.html?rkey=20171106C7678&filter=8242
Vorbörslich soeben rausgekommen!!
chinasky
Q.4/ Fiscal Year 2017 - Conference Call - 28.06.17
Zitat:"MARKHAM, ON, June 16, 2017 /CNW/ - MedReleaf Corp. (TSX: LEAF), Canada's first and only ISO 9001 certified cannabis producer, today announced that it will hold a conference call to discuss its fourth quarter and fiscal year 2017 results on Wednesday, June 28, 2017 at 8:00 a.m. (ET). The call will be hosted by Neil Closner, Chief Executive Officer, and Igor Gimelshtein, Chief Financial Officer, followed by a question and answer period. MedReleaf will report its financial results in the morning prior to the call." ENDE Zitat
https://investors.medreleaf.com/press-releases/press-release-details/2017/MedReleaf-Corp-to-Host-Fourth-Quarter-and-Fiscal-Year-2017-Conference-Call/default.aspx
chinasky
(unknown) Analyst Coverage - Buy Target C$14,-
Zitat:" Initiating coverage: MedReleaf Corp. BUY- LEAF-TSX, June 14, 2017
Target: C$14.00
MedReleaf produces and sells medical cannabis in Canada. The company was
one of the early applicants with Health Canada, providing it with a first mover
advantage. MedReleaf’s profitability is impressive with trailing twelve months
EBITDA levels that exceed all of the other public peers combined. The
company’s products are well perceived by users enabling MedReleaf to
charge a premium price. This, combined with the lowest production costs in
the industry, explains the company’s high profitability......Proceeds from the IPO will be used to fund expansion at the Bradford facility......which is expected to quadruple MedReleaf’s capacity to 35,000kg annually.This is expected to support the company’s entrance in the recreational
market which, at $5b, is expected to be 10x larger than the medical market.
We are initiating coverage of LEAF with a BUY....." ENDE Zitat
Full Article/Source:http://www.stockhouse.com/companies/bullboard?symbol=t.leaf&postid=26378981